These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32574388)

  • 21. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.
    Umemura S; Mimaki S; Makinoshima H; Tada S; Ishii G; Ohmatsu H; Niho S; Yoh K; Matsumoto S; Takahashi A; Morise M; Nakamura Y; Ochiai A; Nagai K; Iwakawa R; Kohno T; Yokota J; Ohe Y; Esumi H; Tsuchihara K; Goto K
    J Thorac Oncol; 2014 Sep; 9(9):1324-31. PubMed ID: 25122428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel nonsense CDC73 mutations in Chinese patients with parathyroid tumors.
    Siu WK; Law CY; Lam CW; Mak CM; Wong GW; Ho AY; Ho KY; Loo KT; Chiu SC; Chow LT; Tong SF; Chan AY
    Fam Cancer; 2011 Dec; 10(4):695-9. PubMed ID: 21732217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Large intragenic deletion of CDC73 (exons 4-10) in a three-generation hyperparathyroidism-jaw tumor (HPT-JT) syndrome family.
    Guarnieri V; Seaberg RM; Kelly C; Jean Davidson M; Raphael S; Shuen AY; Baorda F; Palumbo O; Scillitani A; Hendy GN; Cole DEC
    BMC Med Genet; 2017 Aug; 18(1):83. PubMed ID: 28774260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genotype of CDC73 germline mutation determines risk of parathyroid cancer.
    Li Y; Zhang J; Adikaram PR; Welch J; Guan B; Weinstein LS; Chen H; Simonds WF
    Endocr Relat Cancer; 2020 Sep; 27(9):483-494. PubMed ID: 32590342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CDC73-related hereditary hyperparathyroidism: five new mutations and the clinical spectrum.
    Frank-Raue K; Haag C; Schulze E; Keuser R; Raue F; Dralle H; Lorenz K
    Eur J Endocrinol; 2011 Sep; 165(3):477-83. PubMed ID: 21652691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A germline mutation of HRPT2/CDC73 (70 G>T) in an adolescent female with parathyroid carcinoma: first case report and a review of the literature.
    Serrano-Gonzalez M; Shay S; Austin J; Maceri DR; Pitukcheewanont P
    J Pediatr Endocrinol Metab; 2016 Sep; 29(9):1005-12. PubMed ID: 27544721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism.
    Masi G; Barzon L; Iacobone M; Viel G; Porzionato A; Macchi V; De Caro R; Favia G; Palù G
    Endocr Relat Cancer; 2008 Dec; 15(4):1115-26. PubMed ID: 18755853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Outcomes of Parathyroidectomy in Hyperparathyroidism-Jaw Tumor Syndrome: Analysis of Five Families with CDC73 Mutations.
    Iacobone M; Camozzi V; Mian C; Pennelli G; Pagetta C; Casal Ide E; Masi G; Zovato S; Torresan F
    World J Surg; 2020 Feb; 44(2):508-516. PubMed ID: 31493194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Comparative Genomic Analysis of Parathyroid Adenomas and Carcinomas Harboring Heterozygous Germline CDC73 Mutations.
    Li Y; Simonds WF; Chen H
    J Clin Endocrinol Metab; 2024 Jul; ():. PubMed ID: 39044678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetics and Epigenetics of Parathyroid Carcinoma.
    Marini F; Giusti F; Palmini G; Perigli G; Santoro R; Brandi ML
    Front Endocrinol (Lausanne); 2022; 13():834362. PubMed ID: 35282432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parathyroid Cancer in the Pediatric Patient.
    Davidson JT; Lam CG; McGee RB; Bahrami A; Diaz-Thomas A
    J Pediatr Hematol Oncol; 2016 Jan; 38(1):32-7. PubMed ID: 26650250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor Mutational Burden and Genomic Alterations in Chinese Small Cell Lung Cancer Measured by Whole-Exome Sequencing.
    Su S; Zou JJ; Zeng YY; Cen WC; Zhou W; Liu Y; Su DH; Zhang XL; Huang HY; Lei A; Huang ZH; Jin Y; Li L; Su N; Xie YL; Zhao ZG; Liu JX
    Biomed Res Int; 2019; 2019():6096350. PubMed ID: 31781628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinicopathological features of lung metastases of parathyroid cancinoma.
    Li Q; Shi Z; Zhou X; Xu M; Zhao T; Wei B; Zhang Y; Liu H; Tian Z; Zhang Y; Lu J
    Pathol Res Pract; 2024 Aug; 260():155449. PubMed ID: 38981345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer.
    Adamson AW; Ding YC; Steele L; Leong LA; Morgan R; Wakabayashi MT; Han ES; Dellinger TH; Lin PS; Hakim AA; Wilczynski S; Warden CD; Tao S; Bedell V; Cristea MC; Neuhausen SL
    J Ovarian Res; 2023 Jul; 16(1):141. PubMed ID: 37460928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic profiling as a clinical tool in advanced parathyroid carcinoma.
    Kutahyalioglu M; Nguyen HT; Kwatampora L; Clarke C; Silva A; Ibrahim E; Waguespack SG; Cabanillas ME; Jimenez C; Hu MI; Sherman SI; Kopetz S; Broaddus R; Dadu R; Wanland K; Williams M; Zafereo M; Perrier N; Busaidy NL
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):1977-1986. PubMed ID: 31309300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parathyroid carcinoma: molecular therapeutic targets.
    Marini F; Giusti F; Palmini G; Aurilia C; Donati S; Brandi ML
    Endocrine; 2023 Sep; 81(3):409-418. PubMed ID: 37160841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parathyroid carcinoma.
    Salcuni AS; Cetani F; Guarnieri V; Nicastro V; Romagnoli E; de Martino D; Scillitani A; Cole DEC
    Best Pract Res Clin Endocrinol Metab; 2018 Dec; 32(6):877-889. PubMed ID: 30551989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism.
    van der Tuin K; Tops CMJ; Adank MA; Cobben JM; Hamdy NAT; Jongmans MC; Menko FH; van Nesselrooij BPM; Netea-Maier RT; Oosterwijk JC; Valk GD; Wolffenbuttel BHR; Hes FJ; Morreau H
    J Clin Endocrinol Metab; 2017 Dec; 102(12):4534-4540. PubMed ID: 29040582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.